A prospective study of adherence to lenalidomide for multiple myeloma using Medication Event Monitoring System (MEMS) caps

Alice E. Silberstein, Mark A. Fiala, Kah Poh Loh, Theresa Cordner, Hira Mian, Tanya M Wildes
doi: https://doi.org/10.1101/2022.05.30.22275780

Article Information

doi 
https://doi.org/10.1101/2022.05.30.22275780
History 
  • May 31, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Alice E. Silberstein1,
  2. Mark A. Fiala1,2,
  3. Kah Poh Loh3,
  4. Theresa Cordner1,
  5. Hira Mian4 and
  6. Tanya M Wildes*,5
  1. 1Washington University School of Medicine, St. Louis, MO, USA
  2. 2College for Public Health and Social Justice, Saint Louis University, St. Louis, MO, USA
  3. 3Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
  4. 4McMaster University, Hamilton, ON, Canada
  5. 5Cancer & Aging Research Group, St Louis, MO, USA
  1. ↵*Corresponding author, email tmwildes{at}outlook.com
Back to top
Posted May 31, 2022.
Download PDF
Data/Code
Email
A prospective study of adherence to lenalidomide for multiple myeloma using Medication Event Monitoring System (MEMS) caps
Alice E. Silberstein, Mark A. Fiala, Kah Poh Loh, Theresa Cordner, Hira Mian, Tanya M Wildes
medRxiv 2022.05.30.22275780; doi: https://doi.org/10.1101/2022.05.30.22275780
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area